Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease

[1]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[2]  A. Parkhomenko,et al.  Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. , 2016, JAMA cardiology.

[3]  C. Frost,et al.  Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis , 2016, Journal of clinical pharmacology.

[4]  A. Shenker,et al.  Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban , 2016, Journal of clinical pharmacology.

[5]  P. Schulman,et al.  Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.

[6]  B. Meier,et al.  Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. , 2016, International journal of cardiology.

[7]  B. Meier,et al.  Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  P. Serruys,et al.  Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  E. Antman,et al.  Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial , 2015, Circulation.

[10]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  D. De Bacquer,et al.  Dose-finding study of rivaroxaban in hemodialysis patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  Saibal Kar,et al.  Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[13]  S. Yusuf,et al.  Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. , 2015, Journal of the American College of Cardiology.

[14]  K. Phan,et al.  Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  T. Potpara,et al.  Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  A. Santoro,et al.  Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  E. Edelman,et al.  Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.

[18]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[19]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[20]  Eli N. Deal,et al.  Apixaban Use Among Patients With Severe Renal Impairment , 2014, The Annals of pharmacotherapy.

[21]  F. Mori,et al.  Periprocedural intracardiac echocardiography for left atrial appendage closure: a dual-center experience. , 2014, JACC. Cardiovascular interventions.

[22]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[23]  D. Singer,et al.  Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. , 2014, American heart journal.

[24]  J. Healey,et al.  Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. , 2014, Annals of cardiothoracic surgery.

[25]  S. Yusuf,et al.  Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.

[26]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[27]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[28]  P. Neužil,et al.  Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial , 2013 .

[29]  F. Ronco,et al.  Percutaneous left atrial appendage closure in awake non intubated patient: Multimodality intraprocedural imaging. , 2012, Cardiovascular revascularization medicine : including molecular interventions.

[30]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[31]  C. Clase,et al.  Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  D. Singer,et al.  Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. , 2011, European heart journal.

[33]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[34]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[35]  Elsayed Z Soliman,et al.  Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2011, Circulation. Arrhythmia and electrophysiology.

[36]  A. Go,et al.  Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). , 2010, American heart journal.

[37]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[38]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[39]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[40]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[41]  D. Singer,et al.  Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.

[42]  Timothy Watson,et al.  Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited , 2009, The Lancet.

[43]  Maria Grazia Valsecchi,et al.  Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[45]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[46]  OPL095 Worldwide experience of percutaneous left atrial appendage transcatheter occlusion (PLAATO) , 2005, Journal of the Neurological Sciences.

[47]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[48]  E. Lonn,et al.  Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. , 2003, American heart journal.

[49]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[50]  D. Singer,et al.  Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.

[51]  A. Camm,et al.  Left atrial appendage: structure, function, and role in thromboembolism , 1999, Heart.

[52]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[53]  D. Singer,et al.  Recent national patterns of warfarin use in atrial fibrillation. , 1998, Circulation.

[54]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[55]  J. Madden.  Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. , 1949, Journal of the American Medical Association.